Stocktoria
Pelthos Therapeutics Inc. PTHS
Pelthos Therapeutics Inc. (PTHS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $16.8M at a -257.9% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Manufacturing · percentile among 1829 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.21 |
| Retained earnings / assets | -0.497 |
| EBIT / assets | -0.249 |
| Equity / liabilities | 0.425 |
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
FAQ
Is PTHS financially healthy?
Pelthos Therapeutics Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PTHS pay a dividend?
No, Pelthos Therapeutics Inc. does not currently pay a dividend.
How profitable is PTHS?
In FY2025, Pelthos Therapeutics Inc. had a net margin of -257.9% and a return on equity of -111.4%.
Source: SEC EDGAR filings · CIK 0001919246 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.